Expert Perspectives on the Evolving SGLT Inhibition Treatment Landscape

Heart failure (HF) is a global public health issue with 6.7 million cases reported in the United States and is associated with significant morbidity and mortality despite the availability of guidelines and evidence-based treatments. Reducing the burden of HF on patients and the US healthcare system is a public health priority.   

The therapeutic landscape for HF has evolved significantly in the last 30 years, requiring frequent updates to guidelines as newer therapies that have demonstrated favorable outcomes become available. 

Join our panel of experts for this timely symposium on the role of sodium-glucose cotransporter 2 (SGLT) inhibition in HF prevention and treatment, and how to implement this strategy in tailored guideline-directed medical therapy treatment plans in accordance with the latest clinical evidence and guideline recommendations.

An accredited satellite program, provided by Medscape and supported through an independent educational grant from Lexicon Pharmaceuticals, Inc.